Trial Profile
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 25 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2020.
- 26 Feb 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 16 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.